Comparative Effectiveness and Safety of Standard-Dose and Low-Dose Pembrolizumab in Patients with Non-Small-Cell Lung Cancer: A Multi-Institutional Cohort Study in Taiwan.

Cancers (Basel) · 2022 · PMC8909459 · PMID 35267465

Europe PMC DOI

hedged sentence

0.1500

closest p · 3.0× alpha

0.1500

boldest claim

The sentences

did not reach statistical significancep = 0.15not close (p > 0.1)

After IPTW adjustment, the median OS was longer in the standard-dose group but did not reach statistical significance compared with the low-dose group (19.3 vs. 14.3 months, log-rank p = 0.15) ( Figure 2 a).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.